The A4 study is a landmark clinical trial to prevent the memory loss associated with Alzheimer’s disease for older individuals ages 65-85 who may be at risk but who have normal memory function.

You may be eligible to participate in the A4 study if you:

- Are 65 to 85 years old.
- Have normal thinking and memory abilities.
- Have an A4 study partner who has at least weekly contact with you and can answer questions once a year.
- Are willing and able to receive intravenous infusion (IV) of the investigational treatment or placebo (monthly infusions).

A4 participants must be willing and able to participate in all required procedures for the duration of the A4 study.

A4 Study Organizers

The A4 study is a landmark public-private partnership, funded by the National Institute on Aging/NIH, Eli Lilly and Company, and several philanthropic organizations. The A4 trial is coordinated by the University of Southern California’s Alzheimer’s Therapeutic Research Institute, with study sites in multiple locations.

Interested in learning more?

Phone: 844-A4STUDY (247-8839)
Email: A4-participate@usc.edu
A4study.org

A4study.org
The purpose of the A4 study (also known as the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s study) is to test whether a new investigational treatment, called an anti-amyloid antibody, can slow memory loss associated with Alzheimer’s disease (AD).

What is involved in the study?
Participants enrolled in the A4 study will visit the clinical research site once a month for approximately three years and will need to have a “study partner.”

Half the participants in the A4 study will receive the investigational treatment, and half will receive a “placebo” (an inactive substance designed to mimic the appearance of a drug). The investigational treatment and the placebo are given by an intravenous infusion (IV) every month.

Your health will be monitored throughout the study using assessments such as:

- Memory and thinking tests
- ECGs (a look at your heart)
- PET scan (can identify the buildup of amyloid plaques thought to be associated with AD)
- MRI scans (captures a picture of your brain)
- Blood and urine tests

Are there risks involved in the A4 study?
All clinical studies, including the A4 study, may involve some risks associated with participation. If you are considering participation in A4, you will have detailed discussions with physicians and research staff regarding the investigational treatment and other aspects of the A4 study.

Amyloid is a protein normally produced in the brain that can build up in older people, forming amyloid plaque deposits. Scientists believe this buildup of deposits may play a key role in the eventual development of AD-related memory loss.

How will I know whether it is the right time for me to participate?
Physicians and researchers will use PET amyloid imaging scans to determine whether a potential participant has evidence of the elevated brain amyloid buildup associated with the development of AD-related symptoms in many people.

Individuals with elevated amyloid confirmed through a PET scan may be eligible to become a participant in the A4 clinical trial.

People who do not show changes in the brain associated with AD may be asked to participate in a separate study. This group will not receive the investigational drug but will complete the same memory tests every six months to compare changes in cognition over time.

The A4 Study
NOW IS THE TIME

A4study.org/locations

There are over 60 study sites across the U.S., Canada, and Australia.